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During the last 40 years improved understanding of the pathology 
of lung cancer has prompted substantial changes in the histologic 
classiﬁcation by the World Health Organization (WHO). Substantial 
changes in histologic subclassiﬁcation by the WHO from the 1967 to 
1981, to 1999, and to 2004 classiﬁcation have reﬂected the evolution 
of changes in epidemiology, demographics and in our understanding 
on the molecular basis of lung cancer. From 1967 to 1999 multiple 
subcategories were added to reﬂect increasing recognition of the 
histologic heterogeneity of lung cancer. The signiﬁcant changes in the 
1999 WHO classiﬁcation (1) included a thorough subclassiﬁcation of 
adenocarcinoma, the identiﬁcation and description of a preinvasive le-
sion for adenocarcinoma, the atypical adenomatous hyperplasia (AAH), 
and a detailed subclassiﬁcation of squamous dysplasias and carcinoma 
in situ based on objective and speciﬁc criteria. Large cell carcinoma has 
been divided in two main variants with strong prognostic signiﬁcance 
: the large cell carcinoma and the basaloid carcinoma ; a new class of 
sarcomatoid carcinoma has been created. All these major changes were 
preserved with the 2004 WHO classiﬁcation (2) which include morpho-
logic deﬁnition, differential diagnosis, clinico-radiological context and 
genetic information for each histological class.
Squamous cell carcinoma
There was no change in the deﬁnition: a proliferation of cells show-
ing keratinization and/or intercellular bridges, the level of which allow 
grading from poorly differentiated to well differentiated squamous cell 
carcinoma. Variants include: papillary, clear cell, small cell (not to be 
confused with small cell lung carcinoma) and basaloid carcinoma, the 
last having poor prognosis as compared to other squamous cell or non 
small cell carcinoma (3).
Small cell lung carcinoma
Small cell lung carcinoma have retained their previous deﬁnition: 
a proliferation of densely packed small cells with high nuclear to 
cytoplasmic ratio, dense chromatin, inconspicuous nucleoli, nuclear 
molding, high mitotic rate and large areas of necrosis. The only variant 
retained in the revised WHO classiﬁcation is the small cell carcinoma 
combined (associating a small cell lung carcinoma component with any 
other non small cell lung carcinoma). Both the classical pure small cell 
and the combined variant have the same prognosis and chemosensitiv-
ity. Speciﬁc tumor markers include expression of neuroendocrine mark-
ers (chromogranin, synaptophysin, NCAM) and expression of TTF-1 
(Thyroid Transcription Factor) in 85 % of the cases. 
Adenocarcinoma
Changes in epidemiology demographics, new molecular biology 
knowledge, and HR CT-scanning have led to changes in the WHO 
classiﬁcation of adenocarcinoma, with increasing recognition of het-
erogeneity of lung adenocarcinoma, adenocarcinoma mixed subtypes 
was added to the previous classes (acinar, papillary, bronchioloalveolar, 
solid) and moved to the top of the list of subcategories in 2004 since 
it is now the most common subtypes accounting for 85 % of our diag-
nosis of lung adenocarcinoma. Bronchioloalveolar carcinoma (BAC) 
was also strongly modiﬁed and received a very restrictive deﬁnition, 
and distinction of 3 cell types, non mucinous, mucinous, and mixed 
mucinous and non mucinous. The non mucinous BAC consists of 
type II pneumocytes and Clara cell types which express TTF-1. Thirty 
percent of them display EGF-R mutation. Mucinous type BAC disclose 
Ras mutation more frequently than EGF-R mutation as adenocarcinoma 
without BAC pattern. The most signiﬁcant change in the 1999 WHO 
classiﬁcation was the requirement that all BACs demonstrate pure 
lepidic growth without any kind of invasion in stroma, blood vessels 
or pleura. As compared to the previous WHO classiﬁcation where no 
requirement for the amount (of non-invasive) BAC component was 
emphasized, most lung adenocarcinoma with BAC component are 
now classiﬁed as adenocarcinoma mixed subtype, due to the presence 
of the invasive patterns which represent all other adenocarcinoma 
architectures like acinar, papillary, or solid. Papillary adenocarcinoma 
is like BAC prone for frequent mutation in parallel with sensitivity to 
tyrosine-kinase inhibitors. A group of uncommon variants were added 
to the adenocarcinoma subclassiﬁcation in recognition that they are 
primary lung cancer although mimicking carcinoma from other sites, 
particularly from digestive tracts. Another major change in the WHO 
classiﬁcation was the addition of atypical adenomatous hyperplasia 
(AAH), an atypical bronchioloalveolar proliferation that ressembles but 
fall short for criteria for BAC. AAH is a millimetric lesion that usually 
measures less than 5 mm. The narrow deﬁnition of BAC has rendered 
most of the literature on BAC obsolete because it reports on adenocar-
cinoma mixed subtype with a BAC component. It has been shown that 
BAC deﬁned as a non invasive proliferation has an excellent prognosis 
of 100 % more than 5-year survival (4). There is a 90 % correlation be-
tween BAC (pure) and AAH with ground glass opacity nodule (GGO) 
on HR or CT. Adenocarcinoma (with or without BAC) may present as 
unique solitary nodule (T1 or T2), or multiple nodules that can be uni 
or bilateral receiving the classiﬁcation T4 in the current TNM when the 
satellite nodules are in the same lobe, or M1 when they are distrib-
uted in more than one lobe. Lobar consolidation patterns frequent in 
adenocarcinoma with BAC features and pseudopneumonic pattern 
receive the T4 or M1 classiﬁcation. A signiﬁcantly better survival of 
these multicentric adenocarcinoma as compared to T4 and M1 from 
other descriptors of the TNM inﬂuenced propositions for changes in 
the TNM classiﬁcation (new proposition for TNM classiﬁcation (JTO 
2007, in press).
Criterias for minimal invasion in BAC has issued from several 
Japanese studies and it is obvious that the percentage of BAC versus in-
vasive component in lung adenocarcinoma is prognostically important 
in these series. However at the present time, a consensus deﬁnition of 
minimally invasive BAC with a favorable prognostic close to 100 % 
5-year survival was not recommended by the panel of WHO lacking 
compelling evidence that minimal invasion in BAC according to the 
proposed criteria would select a subpopulation with favorable prognos-
tic in heterogeneous genetic population such as North Americans and 
Europeans.
Large cell carcinoma
Large cell carcinoma has been deﬁned not only on the basis of absence 
of differentiation criteria for small cell lung carcinoma, adernocarcino-
ma or squamous cell carcinoma. Two prognostically important variants 
has been deﬁnedon objective criteria: the large cell neuroendocrine car-
cinoma (5) based on neuroendocrine morphology and neuroendocrine 
markers and the basaloid carcinoma (4), a basal stem cell proliferation 
with no squamous differentiation and a high mitotic rate. Both catego-
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ries have a signiﬁcant worse prognosis than other large cell carcinoma 
and other non small cell lung carcinoma after stratiﬁcation per stage.
Adenosquamous carcinoma represent only 2 % of lung tumors.
Sarcomatoid carcinoma
Sarcomatoid carcinoma is a new class deﬁned on the basis of transi-
tional morphology between epithelial and mesenchymal tumors. The 
most frequent subtype of sarcomatoid carcinoma is the pleomorphic 
carcinoma characterized by an association of pseudosarcomatous 
spindle or giant cells with any conventional type of non small cell lung 
carcinoma. These classes also include pure spindle, or pure giant cell 
carcinoma, carcinosarcoma, and pulmonary blastoma (a biphasic tu-
mor). Pleomorphic carcinoma has been shown to portend dismal prog-
nosis as compared to other non small cell lung carcinoma at stage I.
Carcinoid tumors
Carcinoids tumors has been subclassiﬁed in typical versus atypical 
according to objective criteria: the rate of mitosis (less or more than 2) 
and/or the presence of focal necrosis. Atypical carcinoids have a sig-
niﬁcantly worse prognosis than typical carcinoids as deﬁned with these 
two criteria. The neuroendocrine tumors of the lung encompass three 
categories: the low grade typical carcinoids, the intermediate grade 
atypical carcinoid and the high grade small cell lung carcinoma and 
large cell neuroendocrine carcinoma which have the same molecular 
alteration and survival.
Most of the subtyping of lung cancer can be achieved in any labora-
tory with the use of a few immunohistochemical markers including 
the demonstration of at least one neuroendocrine markers for the 
deﬁnition of large cell neuroendocrine carcinoma and the presence 
of the cytokeratins in the sarcomatoid carcinoma that do not present 
a classical non small cell lung carcinoma component. The relevance 
of this classiﬁcation as regard to epidemiology, and genetics is higher 
than the previous one and several classes gain characteristic clinical 
signiﬁcance and therapeutic relevance. According to objective criteria 
of subclassiﬁcation, it is expected that less than 1 % of lung cancer will 
stay unclassiﬁed.
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The last ﬁve years have witnessed an explosion of knowledge about the 
biology of NSCLC. We have identiﬁed patients who are uniquely sensi-
tive to EGFR inhibitors including patients with mutations in the EGFR 
gene and those with extra copies of the gene as detected by FISH1. 
We have learned about important DNA repair enzymes that predict re-
sponse to platinum based agents in the adjuvant setting2. Perhaps most 
interestingly in 2006 we learned of at least two gene expression proﬁles 
that are able to predict for outcome in lung cancer patients3,4. 
The challenge for those who do clinical research is to ﬁnd ways to 
make this greater understanding of lung cancer biology of relevance to 
the treatment of patients with lung cancer. That will most likely happen 
through two mechanisms. First if we have a better way to prognosticate 
outcome we will be more judicious in how we treat patients. Perhaps 
there is a subset of patients with lung cancer that do not need adjuvant 
chemotherapy. Perhaps there are patients with stage IA who are cur-
rently not being treated who would beneﬁt from treatment. The second 
key application of understanding lung cancer biology is that this holds 
the promise of uncovering new targets. The metagene proﬁles and gene 
signature hold the promise of identifying genes whose role in lung 
cancer was previously unrecognized. Identifying these key genes is the 
ﬁrst step in target validation which will hopefully be followed by more 
effective treatments. 
A second important application of biomarkers in lung cancer clini-
cal trial design involves efforts to come up with relevant intermediate 
endpoints for clinical trials. One of the great successes of modern medi-
cine has been the rapid development of combination therapy for HIV. 
One of the most important aspects of trial design in HIV is that many 
trials employed surrogate endpoints such as viral load which allowed 
quick development of multi-drug combinations without having to wait 
for overall survival endpoints to be reached. In lung cancer there are 
a number of promising biomarkers that might serve in this fashion. 
Quantiﬁcation of circulating tumor cells (CTC) is clearly one such 
approach. Following levels of CTCs in plasma may well correlate with 
outcome. Sequencing of such tumor cells may also provide insight into 
the development of drug resistance. 
Trials conducted in genotypically deﬁned populations offers an op-
portunity to use targeted agents in the most favorable setting. The 
iTARGET study presented at ASCO 2007 by Dr. Lecia Sequist was an 
excellent example of this approach5. In this study Sequist sequenced 89 
patients with lung cancer and identiﬁed a group of 31 harboring EGFR 
mutations to treat with ﬁrst line geﬁtinib. The median PFS of this group 
was over 11 months and the response rate approximately 55%-- both 
values that are far higher than that seen in unselected patient popul-
tions. Similar studies are underway using FISH and randomized studies 
comparing EGFR-TKI to chemotherapy are planned in Asia to validate 
this approach.
One of the hurdles to consider for biomarker trials in lung cancer is the 
difﬁculty in obtaining tissue. Many of our patients are diagnosed using 
a ﬁne needle aspiration. This sample is often not sufﬁcient for adequate 
determination of oncogene ampliﬁcation patterns or mutational status. 
As discussed above CTC offer one possible option. Commitment by 
investigators to obtaining larger core biopsies at the time of diagnosis 
is another technique that can improve yield. Of course serum biomark-
